Beximco Pharmaceuticals Limited (DSE: BXPHARMA)
Bangladesh
· Delayed Price · Currency is BDT
76.50
+1.20 (1.59%)
At close: Sep 12, 2024
Beximco Pharmaceuticals Cash Flow Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
Net Income | 5,330 | 4,614 | 5,123 | 5,128 | 3,515 | 3,033 | Upgrade
|
Depreciation & Amortization | 1,798 | 1,848 | 1,667 | 1,114 | 1,114 | 942.76 | Upgrade
|
Other Amortization | 27.53 | 27.53 | - | - | - | - | Upgrade
|
Loss (Gain) From Sale of Assets | -18.07 | -13.82 | -12.62 | -3.96 | 33.8 | -1.44 | Upgrade
|
Asset Writedown & Restructuring Costs | 184.5 | 184.5 | - | - | - | - | Upgrade
|
Loss (Gain) on Equity Investments | - | - | - | - | - | 29.33 | Upgrade
|
Other Operating Activities | -137.6 | 158.2 | 346.09 | 60.3 | 322.43 | 669.5 | Upgrade
|
Change in Accounts Receivable | -632.66 | -431.84 | 352.25 | 431.61 | 29.51 | -573.45 | Upgrade
|
Change in Inventory | 255.63 | -1,829 | -2,565 | -1,084 | -70.14 | -927.4 | Upgrade
|
Change in Accounts Payable | 1,074 | 1,060 | -9.72 | 587.17 | 371 | 100.1 | Upgrade
|
Change in Income Taxes | 327.48 | 323.65 | -156.05 | -63.38 | 154.27 | -269.23 | Upgrade
|
Change in Other Net Operating Assets | 163.76 | 143.36 | 469.16 | -146.06 | 72.98 | -43.66 | Upgrade
|
Operating Cash Flow | 8,373 | 6,085 | 5,214 | 6,023 | 5,542 | 2,960 | Upgrade
|
Operating Cash Flow Growth | 50.55% | 16.70% | -13.43% | 8.67% | 87.25% | 62.71% | Upgrade
|
Capital Expenditures | -2,036 | -2,411 | -2,815 | -2,521 | -2,244 | -4,416 | Upgrade
|
Sale of Property, Plant & Equipment | 26.12 | 23.35 | 24.06 | 32.83 | 3.65 | 17.54 | Upgrade
|
Cash Acquisitions | - | - | -4,767 | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -375.14 | -231.54 | -124.29 | -37.73 | -31.75 | -128.62 | Upgrade
|
Investment in Securities | -200 | - | - | - | 323.36 | 16.03 | Upgrade
|
Other Investing Activities | 1.65 | 1.93 | 2.02 | 0.94 | 1.43 | 1.49 | Upgrade
|
Investing Cash Flow | -2,583 | -2,617 | -7,680 | -2,525 | -1,947 | -4,510 | Upgrade
|
Short-Term Debt Issued | - | - | 1,508 | - | - | 3,684 | Upgrade
|
Long-Term Debt Issued | - | - | 2,731 | - | - | - | Upgrade
|
Total Debt Issued | -80.69 | - | 4,238 | - | - | 3,684 | Upgrade
|
Short-Term Debt Repaid | - | -229.38 | - | -2,375 | -1,971 | - | Upgrade
|
Long-Term Debt Repaid | - | -1,763 | - | -504.64 | -1,000 | -1,412 | Upgrade
|
Total Debt Repaid | -3,996 | -1,993 | - | -2,880 | -2,971 | -1,412 | Upgrade
|
Net Debt Issued (Repaid) | -4,077 | -1,993 | 4,238 | -2,880 | -2,971 | 2,272 | Upgrade
|
Common Dividends Paid | -1,583 | -1,568 | -1,623 | -578.35 | -601.96 | -505.35 | Upgrade
|
Other Financing Activities | - | - | - | - | - | 0 | Upgrade
|
Financing Cash Flow | -5,660 | -3,561 | 2,615 | -3,458 | -3,573 | 1,767 | Upgrade
|
Foreign Exchange Rate Adjustments | 46.38 | 59.81 | 45.36 | - | 1.97 | 0.22 | Upgrade
|
Net Cash Flow | 176.62 | -32.99 | 194.71 | 40.45 | 24.52 | 216.76 | Upgrade
|
Free Cash Flow | 6,337 | 3,674 | 2,399 | 3,503 | 3,299 | -1,457 | Upgrade
|
Free Cash Flow Growth | 124.13% | 53.15% | -31.51% | 6.17% | - | - | Upgrade
|
Free Cash Flow Margin | 14.71% | 9.36% | 6.92% | 11.88% | 12.88% | -6.38% | Upgrade
|
Free Cash Flow Per Share | 14.21 | 8.24 | 5.38 | 7.85 | 7.39 | -3.26 | Upgrade
|
Cash Interest Paid | 1,165 | 1,272 | 1,002 | 861.45 | 1,013 | 1,032 | Upgrade
|
Cash Income Tax Paid | 1,468 | 1,145 | 1,347 | 1,450 | 932.4 | 1,073 | Upgrade
|
Levered Free Cash Flow | 4,424 | 1,724 | -1,004 | 1,799 | 2,160 | -2,915 | Upgrade
|
Unlevered Free Cash Flow | 5,135 | 2,500 | -425.73 | 2,303 | 2,775 | -2,282 | Upgrade
|
Change in Net Working Capital | -873.1 | 1,047 | 3,266 | 219.48 | -577.5 | 1,722 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.